Menu

Blog

Archive for the ‘biotech/medical’ category: Page 468

Nov 3, 2023

Bartering light for light: Scientists discover new system to control the chaotic behavior of light

Posted by in category: biotech/medical

Harnessing and controlling light is vital for the development of technology, including energy harvesting, computation, communications, and biomedical sensing. Yet, in real-world scenarios, complexity in light’s behavior poses challenges for its efficient control. Physicist Andrea Alù likens the behavior of light in chaotic systems to the initial break shot in a game of billiards.

“In billiards, tiny variations in the way you launch the cue ball will lead to different patterns of the balls bouncing around the table,” said Alù, Einstein Professor of Physics at the CUNY Graduate Center, founding director of the Photonics Initiative at the CUNY Advanced Science Research Center and distinguished professor at CUNY.

“Light rays operate in a similar way in a chaotic cavity. It becomes difficult to model to predict what will happen because you could run an experiment many times with similar settings, and you’ll get a different response every time.”

Nov 3, 2023

UMBC Team Makes First-ever Observation Of A Virus Attaching To Another Virus: University Of Maryland, Baltimore County

Posted by in categories: biotech/medical, mathematics

In a paper published in the Journal of the International Society of Microbial Ecology, a UMBC team and colleagues from Washington University in St. Louis (WashU) describe the first observation of a satellite bacteriophage (a virus that infects bacterial cells) consistently attaching to a helper bacteriophage at its “neck”—where the capsid joins the tail of the virus.

In detailed electron microscopy images taken by Tagide deCarvalho, assistant director of the College of Natural and Mathematical Sciences core facilities and first author on the new paper, 80 percent (40 out of 50) helpers had a satellite bound at the neck. Some of those that did not had remnant satellite tendrils present at the neck. Erill, senior author on the paper, describes them as appearing like “bite marks.”

“When I saw it, I was like, ‘I can’t believe this,’” deCarvalho says. “No one has ever seen a bacteriophage—or any other virus—attach to another virus.”

Nov 3, 2023

Nanoparticles deliver treatment directly to tumors of deadly brain cancer

Posted by in categories: biotech/medical, nanotechnology, neuroscience

Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a particularly deadly brain cancer.

The researchers, led by professors Mark Saltzman and Ranjit Bindra, administered to mice with medulloblastoma a treatment that features specially designed drug-carrying nanoparticles. The study, published in Science Translational Medicine, showed that mice who received this treatment lived significantly longer than mice in the control group.

Medulloblastoma, a that predominantly affects children, often begins with a tumor deep inside the . The cancer is prone to spread along two protective membranes known as the leptomeninges throughout the , particularly the surface of the brain and the CSF.

Nov 3, 2023

Running Large-Scale CRISPR Screens in Human Neurons

Posted by in categories: biotech/medical, genetics, life extension, neuroscience

Identifying therapeutic targets for neurodegenerative conditions is often challenging due to the limited accessibility of reproducible, scalable in vitro cell models. Genome-level CRISPR screens are useful for these studies but performing screens that include the necessary replicates requires billions of cells. Human iPSC-derived cells can provide the needed scale, however, the complex process of directed differentiation is time-consuming, resource-intensive, and rarely feasible. Furthermore, delivering ribonucleases by transfection or transduction is inefficient in human iPSC-derived cells, especially delicate cell types like neurons. As a result, scientists often rely on immortalized cell lines, which do not accurately represent human biology or disease states, to run large-scale CRISPR screens.

In this GEN webinar, two experts will discuss solutions for running large-scale CRISPR screens to identify therapeutic targets for neurodegenerative diseases. They will present ioCRISPR-Ready Cells™: human iPSC-derived cells precision reprogrammed with opti-ox™, that constitutively express Cas9 nuclease, which are built for rapidly generating gene knockouts and CRISPR screens. During the webinar, you’ll learn about two peer-reviewed studies that performed large scale CRISPR knockout screens using opti-ox powered glutamatergic neurons with stable Cas9 expression. The first study demonstrates a loss-of-function genetic screen using a human druggable genome library. The second study investigated possible regulators of the RNA binding motif 3 protein, whose enhanced expression is highly neuroprotective both in vitro and in vivo.

Nov 3, 2023

Paralyzed Man Can Use Feel Again Thanks to Groundbreaking AI

Posted by in categories: biotech/medical, robotics/AI

In the summer of 2020, Keith Thomas dove into a swimming pool and became paralyzed from the chest down. He spent the next six months isolated in the hospital before joining a clinical medical trial that could make history for its use of groundbreaking Artificial Intelligence technology. Five chips were implanted into his brain which connects to a computer that can read his mind and send signals to parts of his body. Inside Edition Digital has more.

Nov 3, 2023

Taking a census of all the immune cells in the human body

Posted by in categories: biotech/medical, computing

A team of environmental and molecular biologists at the Weizmann Institute of Science, working with a colleague from the Edmond and Lily Safra Children’s Hospital and another with The Hebrew University-Hadassah Medical School, all in Israel, has conducted a census of the immune cells that reside in the human body. The group describes their endeavor in a paper published in Proceedings of the National Academy of Sciences.

Prior research has shown that there are many kinds of immune cells in the human body and that they reside in different locations. Most if not all of them have been identified as well. But until now, it was not known how many of each type of cell exist in the average , how much room they take up or how much they weigh. In this new effort, the research team filled in that gap by conducting a three-pronged survey of immune cells in three types of average human bodies—a grown male, a grown woman and a child.

The three-pronged approached involved first studying available literature to obtain as much data as possible regarding the different types of immune cells. The second part involved conducting cell imaging to categorize cell phenotypes and complex immune cell types—a means of describing how much room different immune cells take up, wherever they may live. And the third part consisted of computational techniques to estimate cell numbers in different parts of the body, with which the team was able to calculate weights and mass.

Nov 3, 2023

How a specific metabolite tells cells whether to repair DNA

Posted by in categories: biotech/medical, health, neuroscience

Metabolites called nucleotides are the building blocks of DNA and can impact cancer’s sensitivity or resistance to chemotherapy and radiation in brain cancer. Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite, called GTP, controls responses to radiation and chemotherapy in an unexpected way.

“We learned that if you increase a cell’s GTP levels, it makes it really resistant to radiation or chemotherapy. Lowering GTP levels, the cell becomes much more sensitive,” said Daniel Wahl, M.D., Ph.D., associate professor of radiation oncology at Michigan Medicine and senior author of this paper.

Researchers have long known that levels of nucleotides like GTP control how fast DNA damage is repaired, which in turn controls sensitivity to therapies.

Nov 3, 2023

When will we upload our consciousness to the cloud?

Posted by in categories: biotech/medical, computing, life extension, neuroscience

As long as people have been alive, they’ve wanted to stay alive. For centuries, explorers have searched for the fountain of youth. And today, scientists are hard at work researching technology that can extend the human lifespan, stop or reverse aging; and even preserve a terminally ill person indefinitely, until a cure for their disease is discovered. But what if — instead of preserving our *bodies* — we could preserve our *consciousness*; by uploading it to a powerful computer. This is called *mind uploading*. And one startup has developed a procedure to do exactly this. It’s scientifically sound, there’s a waiting list to participate, and the procedure — is one hundred percent fatal. Let’s find out why.〰
🙏 SUPPORT THE WHY FILES
🙏 https://www.patreon.com/thewhyfiles (Fun, Free Perks!)👽 BUY WHY FILES MERCH
👽 https://shop.thewhyfiles.com (Code: LIZZIDPEEPLE for 10% off first order)💬 CHAT WITH US ON DISCORD
💬 https://thewhyfiles.com/discord〰
🌐 OFFICIAL WEB SITE: https://thewhyfiles.com🕵️ Submit a topic, suggestion or just say hi:
🕵️ https://thewhyfiles.com/tips🎨 Have a product suggestion or want to design artwork for TWF?
🎨 https://thewhyfiles.com/merch📸 BE A WHY FILES MODEL (and get free stuff!)
📸 Send a photo of you/family/friends watching TWF.
📸 wearing TWF gear, using TWF merchandise:
📸 https://thewhyfiles.com/wild〰
🎧 THE PODCAST VERSION
🎧 https://thewhyfiles.com/podcast〰
⁍ TWF on SOCIAL (in order of importance)
https://www.reddit.com/r/TheWhyFiles/
https://twitter.com/OMGTheWhyFiles.
https://www.instagram.com/OMGTheWhyFiles.
https://www.tiktok.com/@thewhyfiles.
https://www.facebook.com/OMGTheWhyFiles〰
🐠 BETTER CHANNELS TO WATCH:
🐠 https://www.youtube.com/c/HecklefishMoriarty.
🤓 https://www.youtube.com/c/TheWhyFilesBackstage.
#science #future #technology

Nov 3, 2023

CRISPR’s Next Advance Is Bigger Than You Think

Posted by in categories: biotech/medical, neuroscience

You’ve probably heard of CRISPR, the revolutionary technology that allows us to edit the DNA in living organisms. Biochemist and 2023 Audacious Project grantee Jennifer Doudna earned the Nobel Prize for her groundbreaking work in this field — and now she’s here to tell us about its next world-changing advancement. She explains how her team at the Innovative Genomics Institute is pioneering a brand new field of science — precision microbiome editing — that uses CRISPR in an effort to solve seemingly insurmountable problems like asthma, Alzheimer’s and climate change.
This ambitious idea is part of the Audacious Project, TED’s initiative to inspire and fund global change.

If you love watching TED Talks like this one, become a TED Member to support our mission of spreading ideas: https://ted.com/membership.

Continue reading “CRISPR’s Next Advance Is Bigger Than You Think” »

Nov 2, 2023

NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic Developed Through Public-Private Partnership

Posted by in categories: biotech/medical, finance, health

A study by the Global Antibiotic Research & Development Partnership and Innoviva Specialty Therapeutics found a single dose of a first-in-class oral antibiotic called zoliflodacin was as safe and effective as standard therapy for uncomplicated urogenital gonorrhea. NIAID contributed financial and scientific support to the development of zoliflodacin and applauds its non-governmental and private sector partners on successfully conducting the study. Read the NIH statement on these results: https://go.nih.gov/Wquuct


A single dose of a novel oral antibiotic called zoliflodacin has been found to be as safe and effective as standard therapy for uncomplicated urogenital gonorrhea in an international Phase 3 non-inferiority clinical trial, according to the Global Antibiotic Research & Development Partnership (GARDP), the study sponsor. Gonorrhea treatment options are increasingly limited due to antimicrobial resistance seen in Neisseria gonorrhoeae, the bacteria that cause gonococcal infection.

Because of the imperative to expand the gonococcal therapeutic pipeline, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has contributed financial and scientific support to the development of zoliflodacin and applauds its non-governmental and private sector partners on successfully conducting the Phase 3 study. This research has generated important new evidence for a field in urgent need of alternative therapeutic options. Specifically, zoliflodacin may offer an alternative to current therapy for uncomplicated urogenital gonococcal infection.

Continue reading “NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic Developed Through Public-Private Partnership” »

Page 468 of 2,808First465466467468469470471472Last